IceCure Medical Showcases FDA-Authorized ProSense Device for Minimally Invasive Breast Cancer Treatment

Reuters11-04

IceCure Medical Showcases FDA-Authorized ProSense Device for Minimally Invasive Breast <a href="https://laohu8.com/S/CTHZ">Cancer Treatment</a>

IceCure Medical Ltd. has announced that its ProSense® system is the first and only medical device to receive U.S. FDA marketing authorization for the local treatment of early-stage low-risk breast cancer in patients aged 70 and above, in combination with adjuvant endocrine therapy. ProSense® utilizes liquid nitrogen-based cryoablation technology as a minimally invasive alternative to surgery, targeting tumors quickly and with minimal pain. The device is approved for use in over 15 countries, including the United States, Europe, Brazil, India, and China, and has received recognition such as the 2024 Scientific Impact Award from the American Society of Breast Surgeons for its ICE3 clinical trial data. Reimbursement pathways have been established, including a CPT Category III code for facility fees related to breast cancer cryoablation. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IceCure Medical Ltd. published the original content used to generate this news brief on November 03, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2580422249?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-04 02:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2580422249","market":"fut","top_or_hot":-1,"title":"IceCure Medical Showcases FDA-Authorized ProSense Device for Minimally Invasive Breast Cancer Treatment","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      IceCure Medical Showcases FDA-Authorized ProSense Device for Minimally Invasive Breast <a href=\"https://laohu8.com/S/CTHZ\">Cancer Treatment</a>\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ICCM\">IceCure Medical Ltd.</a> has announced that its ProSense® system is the first and only medical device to receive U.S. FDA marketing authorization for the local treatment of early-stage low-risk breast cancer in patients aged 70 and above, in combination with adjuvant endocrine therapy. ProSense® utilizes liquid nitrogen-based cryoablation technology as a minimally invasive alternative to surgery, targeting tumors quickly and with minimal pain. The device is approved for use in over 15 countries, including the United States, Europe, Brazil, India, and China, and has received recognition such as the 2024 Scientific Impact Award from the American Society of Breast Surgeons for its ICE3 clinical trial data. Reimbursement pathways have been established, including a CPT Category III code for facility fees related to breast cancer cryoablation. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IceCure Medical Ltd. published the original content used to generate this news brief on November 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IceCure Medical Showcases FDA-Authorized ProSense Device for Minimally Invasive Breast Cancer Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIceCure Medical Showcases FDA-Authorized ProSense Device for Minimally Invasive Breast Cancer Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-04 02:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      IceCure Medical Showcases FDA-Authorized ProSense Device for Minimally Invasive Breast <a href=\"https://laohu8.com/S/CTHZ\">Cancer Treatment</a>\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ICCM\">IceCure Medical Ltd.</a> has announced that its ProSense® system is the first and only medical device to receive U.S. FDA marketing authorization for the local treatment of early-stage low-risk breast cancer in patients aged 70 and above, in combination with adjuvant endocrine therapy. ProSense® utilizes liquid nitrogen-based cryoablation technology as a minimally invasive alternative to surgery, targeting tumors quickly and with minimal pain. The device is approved for use in over 15 countries, including the United States, Europe, Brazil, India, and China, and has received recognition such as the 2024 Scientific Impact Award from the American Society of Breast Surgeons for its ICE3 clinical trial data. Reimbursement pathways have been established, including a CPT Category III code for facility fees related to breast cancer cryoablation. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IceCure Medical Ltd. published the original content used to generate this news brief on November 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ICCM","symbol_name":"IceCure Medical Ltd.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nNDL1XngJR:1","article_id":"2580422249","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2580422249","pubTimestamp":1762194230,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"IceCure Medical Ltd. has announced that its ProSense system is the first and only medical device to receive U.S. FDA marketing authorization for the local treatment of early-stage low-risk breast cancer in patients aged 70 and above, in combination with adjuvant endocrine therapy. ProSense utilizes liquid nitrogen-based cryoablation technology as a minimally invasive alternative to surgery, targeting tumors quickly and with minimal pain. The device is approved for use in over 15 countries, including the United States, Europe, Brazil, India, and China, and has received recognition such as the 2024 Scientific Impact Award from the American Society of Breast Surgeons for its ICE3 clinical trial data. Reimbursement pathways have been established, including a CPT Category III code for facility fees related to breast cancer cryoablation. You can access the full presentation through the link below.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ICCM":"IceCure Medical Ltd.","BK4082":"医疗保健设备"},"translate_title":"IceCure Medical展示FDA授权的用于乳腺癌微创治疗的ProSense设备","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ICCM":0.9},"content_text":"IceCure Medical Showcases FDA-Authorized ProSense Device for Minimally Invasive Breast Cancer Treatment\n\n\nIceCure Medical Ltd. has announced that its ProSense® system is the first and only medical device to receive U.S. FDA marketing authorization for the local treatment of early-stage low-risk breast cancer in patients aged 70 and above, in combination with adjuvant endocrine therapy. ProSense® utilizes liquid nitrogen-based cryoablation technology as a minimally invasive alternative to surgery, targeting tumors quickly and with minimal pain. The device is approved for use in over 15 countries, including the United States, Europe, Brazil, India, and China, and has received recognition such as the 2024 Scientific Impact Award from the American Society of Breast Surgeons for its ICE3 clinical trial data. Reimbursement pathways have been established, including a CPT Category III code for facility fees related to breast cancer cryoablation. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IceCure Medical Ltd. published the original content used to generate this news brief on November 03, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2580422249","isCrawlerRequest":true}